GlassScriptPhysician profile
Jayanti J Panchal
NPI 1164458758
$72,581.31
in general payments reported to CMS, 2019-2025
49 companies · $1,193 in 2025
The $1,193 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,570 · 2020: $7,556 · 2021: $14K · 2022: $28K · 2023: $7,645 · 2024: $5,622 · 2025: $1,193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $3,529.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,930.00 |
| Food and Beverage | $3,529.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $39,637.99 | 2019-2024 | Xarelto |
| Allergan, INC. | $14,253.65 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $7,089.65 | 2021-2024 | |
| Abbvie INC. | $3,525.66 | 2021-2023 | |
| Glaxosmithkline, LLC. | $1,271.77 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Ironwood Pharmaceuticals, INC | $652.92 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $572.13 | 2024-2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $476.45 | 2019-2025 | Airsupra, Farxiga |
| Amgen INC. | $470.32 | 2020-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $443.62 | 2019-2025 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $438.91 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $262.81 | 2021-2023 | |
| Lilly USA, LLC | $262.52 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Stryker Corporation | $253.05 | 2021 | |
| Pfizer INC. | $233.92 | 2020-2021 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayanti Panchal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.